iCAN Board of Directors
Dr. Robin A. Ely
Dr. Ely holds an MD from Georgetown University and completed her residency in family medicine in 1981, with a study in the use of placebo (power of belief) for hospitalized patients. In 1981, Dr. Ely established the Center for Integrative Medicine, utilizing allopathic standard of care along with multimodal approaches including but not limited to: nutrition, cognitive,hyperbaric, ozone, magnetic, Ayurvedic,color, sound,light, herbal, homeopathy, and hydrotherapy. Since 1983, Dr. Ely has been focused on Gaucher Disease, and facilitated the development at NIH and subsequent approval for the first treatment of Gaucher Disease, raising $10 million R&D funds for Genzyme Corporation to bring enzyme treatment to market. In 1984, Dr. Ely co-founded and was the Medical Director of the National Gaucher Foundation. Since 1991, Dr. Ely has played a major role in Israeli Ministry of Health approval of Gaucher treatment. From 2014-2015, Dr. Ely helped fund and execute clinical research at the Lightfield Foundation which oversees the Lightfield technology utilizing information field technology for healing. Dr. Robin Ely joined iCAN as an investor in 2015 and acts as the chief advisor in all clinical and medical related matters to iCAN and its subsidiaries EndoCRO and CannaTech.
Ramie A. Tritt, MD
Ramie A. Tritt, MD is a physician entrepreneur. On the entrepreneurial side Dr. Tritt co-founded Physician Specialty Corp (PSC), a multi-state physician practice management company in 1996, and was its Chairman and President. After taking PSC public on Nasdaq in 1997, Dr. Tritt lead the company with rapid growth and annual revenues north of $100 million, and he stayed with the company until 2002 when the company was sold to Allied Capital, a publicly traded company based in Washington, DC. In recognition of these achievements Dr. Tritt was awarded the Ernst & Young Entrepreneur of the Year award in 1999. Since 2002 his entrepreneurial focus has been on investing in early to mid-stage companies, frequently functioning as an advisor and board member; and over the last ten years Dr. Tritt has also been an active partner in multiple national and international funds which invest in early to midstage companies in multiple industries.
Over the past five years Dr. Tritt has been attending cannabis investment meetings and became a lifetime member of the ArcView Group in 2013. In March 2015 Dr. Tritt became the Founder and Managing Member of TL Partners, LLC, a private investment group, based in Atlanta, GA, which has raised over $2 million dollars for investments in early stage cannabis companies involved in providing ancillary services and products in the cannabis industry. TL Partners brings both capital and strategic resources to the companies it invests in. To date TL Partners has invested in 12 companies in the cannabis industry ranging from software, e-commerce, real estate, distribution and a diversified cannabis investment company. In 2017, Dr. Tritt and David Friedman together launched Panther Opportunity Fund, a cannabis fund which to date has raised $4.5 million of a planned $5 to $10 million fund to lead or co-lead Series A and later stage cannabis companies who are seeking expansion capital and have demonstrated market viability. Dr. Tritt as managing principal of the Panther Opportunity Fund is actively involved in the due diligence, deal structure and the follow up investment support with the portfolio companies. On the medical side, Dr. Tritt is meeting with scientists and clinicians involved in cannabis research and patient care, with the goal of introducing disease specific cannabis treatment solutions into the US marketplace.
Saul Kaye is the Founder and CEO of iCAN and a true leader in the Israeli Cannabis ecosystem, as well as an industry advisor to the Medical Cannabis caucus of the Knesset. Saul is a licensed pharmacist and entrepreneur with both retail and e-commerce experience. He has founded multiple companies panning six countries across the US, Europe, Israel and Australia.